Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson’s Disease?

被引：0
|
作者：
Seok Jong Chung
Han Soo Yoo
Hye Sun Lee
Hyo Eun Jeong
Soo-Jong Kim
Jungsu S. Oh
Jae Seung Kim
Young H. Sohn
Phil Hyu Lee
机构：
[1] Yonsei University College of Medicine,Department of Neurology
[2] Yonsei University College of Medicine,Department of Biostatistics
[3] Yonsei University College of Medicine,Department of Family Medicine
[4] University of Ulsan College of Medicine,Department of Nuclear Medicine, Asan Medical Center
[5] Yonsei University College of Medicine,Severance Biomedical Science Institute
来源：
CNS Drugs | 2018年 / 32卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：971 / 979
页数：8
相关论文
共 50 条
  • [31] Levodopa-induced ocular dyskinesia in Parkinson's disease
    Groetzsch, H.
    Sztajzel, R.
    Burkhard, P. R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (10) : 1124 - 1128
  • [32] Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease
    G. Arabia
    M. Zappia
    D. Bosco
    L. Crescibene
    A. Bagalà
    L. Bastone
    M. Caracciolo
    M. Scornaienghi
    A. Quattrone
    Neurological Sciences, 2002, 23 : s53 - s54
  • [33] Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease
    Arabia, G
    Zappia, M
    Bosco, D
    Crescibene, L
    Bagalà, A
    Bastone, L
    Caracciolo, M
    Scornaienghi, M
    Quattrone, A
    NEUROLOGICAL SCIENCES, 2002, 23 (Suppl 2) : S53 - S54
  • [34] Does continuous delivery of levodopa-carbidopa intestinal gel really improve levodopa induced dyskinesia in severe Parkinson's Disease patients?
    Colin, O.
    Benatru, I.
    Ouerdani, A.
    Lafay-Chebassier, C.
    Houeto, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 14 - 14
  • [35] COMT polymorphism as a genetic factor in levodopa-induced dyskinesia development in Russian patients with Parkinson's disease
    Akhmadeeva, G.
    Khidiyatova, I.
    Gilyazova, I.
    Umutbaev, S.
    Kachemaeva, O.
    Baitimerov, A.
    Galimova, R.
    Magzhanov, R.
    MOVEMENT DISORDERS, 2022, 37 : S560 - S561
  • [36] The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson's disease
    Choi, C
    Sohn, YH
    Lee, JH
    Kim, JS
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2000, 172 (01) : 12 - 16
  • [37] Early use of amantadine to prevent or delay onset of levodopa-induced dyskinesia in Parkinson's disease
    Jahangirvand, A.
    Rajput, A.
    MOVEMENT DISORDERS, 2013, 28 : S207 - S208
  • [38] Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
    Schaeffer, Eva
    Pilotto, Andrea
    Berg, Daniela
    CNS DRUGS, 2014, 28 (12) : 1155 - 1184
  • [39] Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease
    Ivanova, S. A.
    Alifirova, V. M.
    Freidin, M. B.
    Pozhidaev, I. V.
    Fedorenko, O. Y.
    Bokhan, N. A.
    Zhukova, I. A.
    Zhukova, N. G.
    Wilffert, B.
    Loonen, A. J. M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S1039 - S1040
  • [40] Detection of Levodopa Induced Dyskinesia in Parkinson's Disease Patients Based on Activity Classification
    Jalloul, Nahed
    Poree, Fabienne
    Viardot, Geoffrey
    L'Hostis, Philippe
    Carrault, Guy
    2015 37TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC), 2015, : 5134 - 5137
12345